このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Novo Nordisk マネジメント
マネジメント 基準チェック /34
Novo Nordisk'sの CEO はLars Jorgensenで、 Jan2017年に任命され、 の在任期間は 7.58年です。 は、会社の株式の0.002%を直接所有しており、その価値は$ 12.45M 。経営陣と取締役会の平均在任期間はそれぞれ3.5年と6.4年です。
主要情報
Lars Jorgensen
最高経営責任者
n/a
報酬総額
| CEO給与比率 | n/a |
| CEO在任期間 | 7.6yrs |
| CEOの所有権 | 0.002% |
| 経営陣の平均在職期間 | 3.5yrs |
| 取締役会の平均在任期間 | 6.4yrs |
経営陣の近況
更新なし
Recent updates
Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation
Aug 18Novo Nordisk: Growth Only Limited By Manufacturing Capacity
Aug 07Novo Nordisk: Better Buying Opportunities Ahead
Jul 26Novo Nordisk: Buy On Dips
Jul 04Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy
Jun 26Novo Nordisk: Leading The Fight Against Diabetes And Obesity
Jun 18Novo Nordisk: Considerable Growth Beyond Ozempic
May 27The FTC Cracks Down On Novo Nordisk's Ozempic
May 03Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
Apr 26Novo Nordisk: The Moat Won't Last Forever
Apr 09Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
Mar 18Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified
Mar 07Novo Nordisk, A Very Healthy Pharma Stalwart
Feb 28Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
Feb 23Novo Nordisk: Irrational Exuberance Isn't Worth The Risk
Feb 16Novo Nordisk: Outlook For Weight Loss Drugs In 2024
Jan 22Taking Novo Nordisk To The Next Level
Jan 15Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly
Jan 02Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity
Dec 12Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation
Nov 24Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion
Oct 24Novo Nordisk: Catching The Falling Knife Now Could Really Hurt
Sep 22Novo Nordisk: Strong Fundamentals Meet Technical Uptrends
Aug 30Novo Nordisk: Denmark's Coca-Cola
Jul 25The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier
Jul 11Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care
Jun 23CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | DKK 90b |
| Mar 31 2024 | n/a | n/a | DKK 89b |
| Dec 31 2023 | n/a | n/a | DKK 84b |
| Sep 30 2023 | n/a | n/a | DKK 75b |
| Jun 30 2023 | n/a | n/a | DKK 67b |
| Mar 31 2023 | n/a | n/a | DKK 61b |
| Dec 31 2022 | DKK 60m | DKK 17m | DKK 56b |
| Sep 30 2022 | n/a | n/a | DKK 53b |
| Jun 30 2022 | n/a | n/a | DKK 51b |
| Mar 31 2022 | n/a | n/a | DKK 49b |
| Dec 31 2021 | DKK 58m | DKK 17m | DKK 48b |
| Sep 30 2021 | n/a | n/a | DKK 46b |
| Jun 30 2021 | n/a | n/a | DKK 44b |
| Mar 31 2021 | n/a | n/a | DKK 43b |
| Dec 31 2020 | DKK 57m | DKK 14m | DKK 42b |
| Sep 30 2020 | n/a | n/a | DKK 42b |
| Jun 30 2020 | n/a | n/a | DKK 41b |
| Mar 31 2020 | n/a | n/a | DKK 40b |
| Dec 31 2019 | DKK 55m | DKK 14m | DKK 39b |
| Sep 30 2019 | n/a | n/a | DKK 39b |
| Jun 30 2019 | n/a | n/a | DKK 38b |
| Mar 31 2019 | n/a | n/a | DKK 38b |
| Dec 31 2018 | DKK 41m | DKK 11m | DKK 39b |
| Sep 30 2018 | n/a | n/a | DKK 38b |
| Jun 30 2018 | n/a | n/a | DKK 39b |
| Mar 31 2018 | n/a | n/a | DKK 39b |
| Dec 31 2017 | DKK 32m | DKK 9m | DKK 38b |
報酬と市場: Larsの 総報酬 がUS市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。
報酬と収益: Larsの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Lars Jorgensen (58 yo)
7.6yrs
在職期間
DKK 60,100,000
報酬
Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 7.6yrs | DKK 60.10m | 0.0021% DKK 12.7m | |
| Executive VP | 6.5yrs | DKK 21.50m | 0.000010% DKK 60.8k | |
| Executive VP of Product Supply | no data | DKK 22.00m | 0.000060% DKK 365.0k | |
| Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board | no data | DKK 21.30m | データなし | |
| Executive VP of Development & Member of the Management Board | 3.6yrs | DKK 20.90m | データなし | |
| EVP of Research & Early Development | 3.4yrs | DKK 20.90m | データなし | |
| Executive VP of International Operations & Member of the Management Board | no data | データなし | 0.0011% DKK 6.9m | |
| Executive VP of North America Operations & Member of Management Board | no data | データなし | データなし | |
| Executive VP | no data | データなし | データなし | |
| Executive VP of Global People & Organisation and Member of Management Board | 1.4yrs | データなし | データなし | |
| Executive VP of Corporate Development & Member of Management Board | 1.4yrs | データなし | データなし | |
| Head of Investor Relations | no data | データなし | データなし |
3.5yrs
平均在職期間
54yo
平均年齢
経験豊富な経営陣: NVOの経営陣は 経験豊富 であると考えられます ( 3.5年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Independent Director | 9.4yrs | DKK 1.80m | データなし | |
| Independent Chairman of the Board | 7.4yrs | DKK 3.10m | データなし | |
| Vice Chairman of the Board | 3.4yrs | DKK 2.00m | データなし | |
| Independent Director | 5.4yrs | DKK 2.00m | データなし | |
| Independent Director | 6.4yrs | DKK 1.70m | データなし | |
| Independent Director | 6.4yrs | DKK 1.40m | データなし | |
| Non-Independent Director | 7.4yrs | DKK 1.20m | データなし | |
| Independent Director | 2.4yrs | DKK 1.30m | データなし | |
| Employee Representative Director | 2.4yrs | DKK 800.00k | 0% DKK 0 | |
| Employee Non-Independent Representative Director | 6.4yrs | DKK 1.20m | データなし | |
| Employee Representative Non-Independent Director | 6.6yrs | DKK 1.00m | データなし | |
| Employee Representative Director | 2.4yrs | DKK 800.00k | データなし |
6.4yrs
平均在職期間
58.5yo
平均年齢
経験豊富なボード: NVOの 取締役会 は 経験豊富 であると考えられます ( 6.4年の平均在任期間)。